Company news

Context Therapeutics Inc. news in 2022

Context Therapeutics Inc.'s news releases, calls and decks from 2022, newest first.

View company

Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer

December 7, 2022

Context Therapeutics announces bispecific antibody clinical candidate to treat CLDN6+ cancers

December 5, 2022

Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors

November 28, 2022

Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium

November 20, 2022

Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results

November 8, 2022

Context Therapeutics® Amends Cash Guidance, Extends Runway into Q1 2024

September 26, 2022

Context Therapeutics® Reports Second Quarter 2022 Operating and Financial Results

August 10, 2022

Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination

August 1, 2022

Context Therapeutics® Reports First Quarter 2022 Operating and Financial Results

May 10, 2022

Context Therapeutics® Announces Poster Presentation at the Upcoming 2022 ASCO Annual Meeting

May 4, 2022

Context Therapeutics® Announces Encouraging Preclinical Data from Two Programs to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022

April 10, 2022

Context Therapeutics® Reports Full Year 2021 Operating and Financial Results

March 22, 2022

Context Therapeutics® Announces Acceptance of Five Abstracts to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022

March 7, 2022

Context Therapeutics® Strengthens Research & Development Team

January 4, 2022

Decks in 2022